Chinese Japanese Germany Korea


AZD-9291 structure
Chemical Name:
ZAD9291;ADZ9291;AZD-9291;Mereletinib;AZD9291 Base;AZD9291, >=98%;Osimertinib Base;AZD9291,AZD-9291;AZD929/Osimertinib;AZD9291 (free base)
Molecular Formula:
Formula Weight:
MOL File:

AZD-9291 Properties

CAS DataBase Reference


HS Code  29339900

AZD-9291 price More Price(4)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Cayman Chemical 16237 AZD 9291 ≥98% 1421373-65-0 1mg $25 2018-11-13 Buy
Cayman Chemical 16237 AZD 9291 ≥98% 1421373-65-0 5mg $69 2018-11-13 Buy
Cayman Chemical 16237 AZD 9291 ≥98% 1421373-65-0 10mg $113 2018-11-13 Buy
Cayman Chemical 16237 AZD 9291 ≥98% 1421373-65-0 50mg $313 2018-11-13 Buy

AZD-9291 Chemical Properties,Uses,Production


AZD-9291 (Osimertinib) is a oral, third generation, small-molecule epidermal growth factor receptor (EGFR) inhibitor and antineoplastic agent. In addition, it is a Cytochrome P450 3A inhibitor, and Cytochrome P450 3A4 Inducer, and Cytochrome P450 1A2 Inducer, and Breast Cancer Resistance Protein Inhibitor. It is used for the treatment of advanced non-small cell lung cancer (NSCLC) where mutant EGFR form (such as T790M) is often presented. Through suppressing the EGFR-mediated signalling, it cause cell death and inhibit tumour growth in related cancer cells. 


AZD-9291 (Mesylate), also known as Osimertinib, belongs to a third-generation EGFR (epidermal growth factor receptor) inhibitor. It can be used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in case when the cancer cells carry specific mutations (such as T790M) in the epidermal growth factor receptor. It takes effect through directly binding to the certain mutant forms of EGFR (T790M, L858R, and exon 19 deletions) that are frequently found in NSCLC, further causing poor prognosis for late-stage disease. Since it spares wild type EGFR during therapy, it has only limited toxicity.


The collection of ibrutinib (Imbruvica(R), Pharmacyclics Inc.), afatinib, and osimertinib represents the small, yet expanding, group of covalent SMKIs. Ibrutinib is a non-receptor Bruton’s tyrosine kinase inhibitor approved for the treatment of relapsed chronic lymphocytic leukemia. Afatinib, approved for NSCLC in 2013 and squamous NSCLC in 2016, is a second-generation irreversible EGFR inhibitor that targets wild-type EGFR, the mutant T790M EGFR, and HER2. Osimertinib (AZD9291), which was approved by FDA in November 2015, is a third-generation irreversible EGFR inhibitor that selectively targets the mutant T790M EGFR. Rociletinib, which shares a high degree of structural similarity with that of osimertinib, is a promising covalent EGFR inhibitor developed by Clovis Oncology aimed for the treatment of patients with EGFR T790M-mutated NSCLC, until the company terminated its development in May 2016 following a negative vote fromthe FDA’sOncologic Drugs Advisory Committee.


ChEBI: A member of the class of aminopyrimidines that is 4-(1-methylindol-3-yl)pyrimidin-2-amine in which one of the amino hydrogens is replaced by a 2-methoxy-4-[2-(dimethylamino)ethyl](methyl)amino-5-acrylamidophenyl group. Used (as the mesylate salt) for treat ent of EGFR T790M mutation positive non-small cell lung cancer.


AZD 9291 is an irreversible inhibitor of epidermal growth factor receptor (EGFR) sensitizing and T790M resistance mutations (IC50s = 15-17 nM) while sparing the wild-type form of the receptor (IC50 = 480 nM). It binds the related IGF1R and hERG receptors with significantly reduced potency (IC50s = 2.9 and 16.2 μM, respectively). AZD 9291 has been shown to inhibit tumor growth in a xenograft mouse model at oral doses of 5-10 mg/kg and has been tested clinically in patients with advanced EGFR mutant non-small-cell lung cancer.[Cayman Chemical]


AZD-9291 Preparation Products And Raw materials

Raw materials

Preparation Products

AZD-9291 Suppliers

Global( 195)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Nanjing Gold Pharmaceutical Technology Co. Ltd.
025-84209270 15906146951
025-84209270 CHINA 117 55
Henan DaKen Chemical CO.,LTD.
+86-371-55531817 CHINA 22043 58
Beijing Cooperate Pharmaceutical Co.,Ltd.
+86-10-60279497 +86(0)15646567669
+86-10-60279497 CHINA 1530 55
Shanghai Bojing Chemical Co.,Ltd.
+86-21-37127788 CHINA 500 55
Henan Tianfu Chemical Co.,Ltd.
0371-55170693 CHINA 20786 55
Hubei XinRunde Chemical Co., Ltd.
+8615102730682; +8618874586545
02783214688 CHINA 552 55
Nanjing Finetech Chemical Co., Ltd.
025-85710122 17714198479
025-85710122 CHINA 894 55
+86 21 5161 9050/ 5187 7795
+86 21 5161 9052/ 5187 7796 CHINA 16534 60
Jinan Shengqi pharmaceutical Co,Ltd
86+15552594168 CHINA 339 58
Chemwill Asia Co.,Ltd.
86-21-51861608;;; CHINA 24118 58

View Lastest Price from AZD-9291 manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2018-08-21 AZD-9291
US $7.00 / KG 1KG 99% 1000KG career henan chemical co
2018-08-15 AZD-9291
US $1.00 / KG 1KG 99% 1000KG career henan chemical co
2018-08-15 AZD-9291
US $1.00 / KG 1KG 99% 1000KG career henan chemical co

1421373-65-0(AZD-9291)Related Search:

  • Mereletinib(AZD-9291,Osimertinib)
  • AZD9291 (free base)
  • Osimertinib (AZD-9291)
  • ZAD9291
  • AZD9291, Osimertinib
  • AZD9291 Base
  • Osimertinib Base
  • N-(2-{[2-(Dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin
  • AZD-9291
  • N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide
  • Mereletinib mesylate(AZD9291)
  • Mereletinib
  • N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide
  • AZD929/Osimertinib
  • Osimertinib Intermediate 4
  • N(2{[2(diMethylaMino)ethyl](Methyl)aMino}4Methoxy5{[4(1Methyl1Hindol3yl)pyriMidin2yl]aMino}phenyl)prop2enaMide
  • N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide
  • AZD9291,AZD-9291
  • 2-Propenamide, N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-
  • AZD9291 N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide
  • N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide AZD9291
  • -
  • 421373-65-0
  • Osimertinib, 98%, a potent and selective mutated forms EGFR inhibitor
  • Pharmaceutical Chemical Anticancer Drug Azd-9291 for for Lung Cancer 1421373-65-0
  • API
  • N1-[2-(Dimethylamino)ethyl]-2-methoxy-N1-methyl-N4-[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]-1,4-benzenetriamine
  • ADZ9291
  • C28H33N7O2
  • Anticancer
  • AZD9291
  • 1421373-65-0
  • Inhibitors
  • AZD9291, >=98%
Copyright 2017 © ChemicalBook. All rights reserved